Universal access


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Universal access

  1. 1. Action Aid International Report Release Function Panel Discussion on Achieving Universal Access: How far, How near 7 April 2006 Summary of Responses from e-discussion for The National Stakeholder Conference
  2. 2. The Query <ul><li>What Universal Access means in terms of Prevention, Treatment, Care and Support </li></ul><ul><li>What are the country specific barriers in scaling up Treatment responses to HIV and AIDS   </li></ul><ul><li>What action is required and by whom to overcome these obstacles and </li></ul><ul><li>What would you see as the five key targets (quantitative and qualitative) that need to be set to reach UA to Prevention, Treatment and Care in our country by 2010? </li></ul>
  3. 3. What Universal Access means… <ul><li>Universal awareness about HIV with an enabling environment for seeking information as well as access to condoms, clean needles and syringes including counselling and testing services. </li></ul><ul><li>Ensuring majority of eligible HIV positive persons have sufficient treatment education and awareness, and that ARV is available, affordable and accessible . </li></ul>
  4. 4. <ul><li>Additionally, it includes access to treatment for co-infections such as HCV, HBV and TB and to substitution drugs such as Buprenorphine and Methadone for de-addiction. </li></ul><ul><li>Importance of active participation of stakeholders, the civil society as well as people living with HIV </li></ul>What Universal Access means…
  5. 5. Barriers in scaling up Treatment <ul><li>Inability to address the concerns and needs of vulnerable, stigmatized and socially excluded populations such as MSM, IDU and sex workers; </li></ul><ul><li>Inadequate care and support services and women and child friendly services; </li></ul><ul><li>Discrimination by health care providers including refusal to provide treatment; </li></ul>
  6. 6. <ul><li>Scarce health infrastructure and systems leading to procurement and delivery difficulties; </li></ul><ul><li>Insufficient supplies, in particular, that of female condom as well as post exposure prophylaxis; </li></ul><ul><li>Inadequate reach of prevention, care and support services at the grass root level; </li></ul><ul><li>lack of political commitment, lop-sided increase in fund flow towards prevention and lack of requisite attention to treatment; </li></ul>Barriers in scaling up Treatment
  7. 7. <ul><li>No available legislation to direct employers on provision of prevention, treatment and care services as part of their corporate social responsibility; </li></ul><ul><li>Failure of current intellectual property framework under TRIPS to provide for manufacture of generic versions of ARV, and </li></ul><ul><li>Inaccessibility of second line ARV therapies or paediatric formulations </li></ul>Barriers in scaling up Treatment
  8. 8. Action required <ul><li>Ensuring provision of care and support services in all health departments rather than limiting them to any one unit </li></ul><ul><li>Rapid scale up of care and support projects; preferably, earmarking funds in the ratio of 50:50 for prevention and treatment, care and support; </li></ul><ul><li>Increasing public-private partnerships to mobilize community resources in an effort to provide for poor PLHIV and orphans; </li></ul>
  9. 9. <ul><li>Revamping health infrastructure facilities and systems; </li></ul><ul><li>Interlinking with Panchayats, health functionaries and NGOs at local grassroots level by SACS; </li></ul><ul><li>Developing crucial linkages between VCTC and TB units to ensure essential TB treatment to PLHIV and promoting VCTC services to the TB affected populations; </li></ul>Action required
  10. 10. <ul><li>Reaching at a consensus with various medical councils on what areas of treatment, care and support can be undertaken by Alternate and Indigenous systems of medicine; </li></ul><ul><li>Launching massive awareness campaigns to provide greater visibility to ARV treatment programmes; </li></ul><ul><li>Mainstreaming HIV in all sectors to ensure greater commitment and responsibility towards HIV issues from all concerned </li></ul>Action required
  11. 11. Prevention Targets <ul><li>80% of all people eligible for BCC, IPC, or requiring counselling, PPTCT and ART services avail the respective services with less than a month’s delay. This target should be achieved within two years of going into the UA program; </li></ul><ul><li>0% increase in high prevalence area; </li></ul><ul><li>100% ICDS centers coverage in providing counselling services; </li></ul>
  12. 12. Prevention Targets <ul><li>100% coverage for voluntary testing of Antenatal Mothers to prevent transmission of HIV to children at Primary Health Centers/ICDS centres through referrals; </li></ul><ul><li>30% of the population in the 15-35 years age-bracket registered for voluntary testing. </li></ul>
  13. 13. Care Targets <ul><li>95% of the High Risk Behaviour Group of people and all who have been exposed to Sexually Transmitted Infections are seen by a Doctor trained in Syndromic Management within three months of exposure; </li></ul><ul><li>Training programs for Treatment Education is started immediately and in two years it covers 95% of all Health Care Workers and Professionals. </li></ul>
  14. 14. Care Targets <ul><li>Leadership, Government, Pharmaceuticals, and Activists join hands and bring down costs of the ARV and Opportunistic infections drugs to just over 10% of the cost-of-production in two years; </li></ul><ul><li>Legislation on provision of ARV treatment, Care and Support by all employers including the Government in one year, and its enforcement by another two years; </li></ul><ul><li>Ensuring 100% of orphan children in ages 6-14 years are given basic amenities and continued education. </li></ul>
  15. 15. Thank You